<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00079716</url>
  </required_header>
  <id_info>
    <org_study_id>SG040-0001</org_study_id>
    <nct_id>NCT00079716</nct_id>
  </id_info>
  <brief_title>Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma</brief_title>
  <official_title>A Phase I, Multi-Dose Study of SGN-40 (Anti-huCD40 mAb) in Patients With Refractory or Recurrent Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seagen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and activity of SGN-40 in a weekly&#xD;
      dosage schedule as a single agent.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multi-dose, single-arm, phase I, dose-escalation study to define the&#xD;
      toxicity profile, maximum tolerated dose (MTD), pharmacokinetics, and antitumor activity of&#xD;
      SGN-40 in patients with refractory or recurrent multiple myeloma.&#xD;
&#xD;
      A minimum of three patients will be entered into each dose-level cohort. All patients will&#xD;
      receive a dose-loading schedule during the first two weeks. The maximum weekly dose will be&#xD;
      16mg/kg.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events and lab abnormalities.</measure>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGN-40 (anti-huCD40 mAb)</intervention_name>
    <description>0.5-8 mg/kg IV (in the vein) on Day 1; 0-8 mg/kg on Day 4; 0.5-16 mg/kg on Days 8 and 15; 0-16 mg/kg on Day 29.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>dacetuzumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have refractory or recurrent secretory multiple myeloma (MM).&#xD;
&#xD;
          2. Patients must have failed at least two different prior systemic therapies for MM.&#xD;
&#xD;
          3. Patients may have received a maximum of five cytotoxic regimens.&#xD;
&#xD;
          4. Patients who have received any of the following must complete within the specified&#xD;
             time frame below:&#xD;
&#xD;
               -  Autologous stem cell transplant - 12 weeks prior to first dose&#xD;
&#xD;
               -  Nitrogen Mustard agents, Melphalan, BCNU, IVIG, or monoclonal antibody therapy -&#xD;
                  6 weeks prior to first dose&#xD;
&#xD;
               -  Chemotherapy, Radiation, or other therapies for MM - 4 weeks prior to first dose&#xD;
&#xD;
          5. Patients who have not undergone autologous stem cell transplantation must be either&#xD;
             ineligible for stem cell transplantation or, if eligible, must have refused treatment&#xD;
             by autologous stem cell transplantation.&#xD;
&#xD;
          6. Patients must have an ECOG performance status of ≤ 2 and a life expectancy &gt; three&#xD;
             months.&#xD;
&#xD;
          7. Patients must be available for periodic blood sampling, study-related assessments, and&#xD;
             management of toxicity at the treating institution for the entire duration of the&#xD;
             study.&#xD;
&#xD;
          8. Patients must be at least 18 years of age.&#xD;
&#xD;
          9. Females of childbearing potential must have a negative β-HCG pregnancy test result&#xD;
             within three days of enrollment. All patients must plan to use an effective&#xD;
             contraceptive method during the course of the study.&#xD;
&#xD;
         10. Patients must meet baseline lab data requirements.&#xD;
&#xD;
         11. Patients must give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with non-secretory MM or solitary plasmacytoma or plasma cell leukemia.&#xD;
&#xD;
          2. Patients with a history of allogeneic transplantation.&#xD;
&#xD;
          3. Patients receiving plasmapheresis within four weeks prior to enrollment.&#xD;
&#xD;
          4. Patients undergoing major surgery within four weeks prior to enrollment.&#xD;
&#xD;
          5. Patients with a known hypersensitivity to recombinant proteins or any excipient&#xD;
             contained in the drug formulation.&#xD;
&#xD;
          6. Patients with a history of other malignancies during the past five years with the&#xD;
             exception of adequately treated basal or squamous cell skin cancer or cervical&#xD;
             carcinoma in situ.&#xD;
&#xD;
          7. Patients with any active viral, bacterial, or systemic fungal infection within four&#xD;
             weeks of enrollment.&#xD;
&#xD;
          8. Patients with a history of significant chronic or recurrent infections requiring&#xD;
             treatment.&#xD;
&#xD;
          9. Patients with a history of active thrombosis within three months of enrollment.&#xD;
&#xD;
         10. Patients with a history of pulmonary embolism.&#xD;
&#xD;
         11. Patients with a history of migraines or severe headaches requiring medical therapy&#xD;
             within 12 months of enrollment.&#xD;
&#xD;
         12. Patients who are pregnant or breastfeeding.&#xD;
&#xD;
         13. Patients with uncontrolled hypercalcemia.&#xD;
&#xD;
         14. Patients with any serious underlying medical condition that would impair their ability&#xD;
             to receive or tolerate the planned treatment.&#xD;
&#xD;
         15. Patients with dementia or altered mental status that would preclude understanding and&#xD;
             rendering of informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy Whiting, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Seagen Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>James R. Berenson M.D., Inc.</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/20133895</url>
    <description>Related Info</description>
  </link>
  <results_reference>
    <citation>Hayashi T, Treon SP, Hideshima T, Tai YT, Akiyama M, Richardson P, Chauhan D, Grewal IS, Anderson KC. Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. Br J Haematol. 2003 May;121(4):592-6.</citation>
    <PMID>12752100</PMID>
  </results_reference>
  <results_reference>
    <citation>Hussein M, Berenson JR, Niesvizky R, Munshi N, Matous J, Sobecks R, Harrop K, Drachman JG, Whiting N. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica. 2010 May;95(5):845-8. doi: 10.3324/haematol.2009.008003. Epub 2010 Feb 4.</citation>
    <PMID>20133895</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>March 11, 2004</study_first_submitted>
  <study_first_submitted_qc>March 15, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2004</study_first_posted>
  <last_update_submitted>December 17, 2014</last_update_submitted>
  <last_update_submitted_qc>December 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2014</last_update_posted>
  <responsible_party>
    <name_title>Nancy Whiting, PharmD</name_title>
    <organization>Seattle Genetics, Inc.</organization>
  </responsible_party>
  <keyword>Antigens, CD40</keyword>
  <keyword>Antibody, Monoclonal</keyword>
  <keyword>Blood Coagulation Disorders</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Hemorrhagic Disorders</keyword>
  <keyword>Hemostatic Disorders</keyword>
  <keyword>Immunoproliferative Disorders</keyword>
  <keyword>Lymphoproliferative Disorders</keyword>
  <keyword>Paraproteinemias</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Antibody-Dependent Cell Cytotoxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dacetuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

